25riskM

Market Quick Take - July 15, 2020

Macro 3 minutes to read

Summary:  Another volatile session yesterday in the US as the sell-off from the close of the previous day continued in early trading but was scooped up quickly, in part on very dovish language from the US Federal Reserve. After the New York close the positive tone extended on news that Moderna's Covid-19 vaccine showed promising results in all patients tested. The overnight action was generally positive in Asia despite the Trump administration moving against the special trading status for Hong Kong.


What is our trading focus?

  • US500.I (S&P 500 Index) and USNAS100.I (NASDAQ 100 Index) – yesterday’s session was somewhat of a mirror image of the prior day’s session, as new local lows in the megacap-heavy Nasdaq-100 Index were quickly gathered up and the broader market closed stronger on the day, with the S&P500 putting in a rare outperformance on what proved a positive session on balance. Is this a sign of a rotation away from the focus on the most speculative names? The S&P500 was higher overnight on vaccine hopes and is very close to the post-meltdown highs around 3,220.

  • DAX.I (German DAX Index) - a technical focus on German stocks here as the DAX index is within striking distance of the post COVID-19 meltdown highs just shy of 13,000.

  • Goldman Sachs (GS:xnys) and United Health (UNH:xnys) - both of which reporting earning today, with Goldman Sachs reporting at 11:30 GMT and United Health likewise also reporting ahead of the US open.

  • Moderna, Inc. (MRNA:xnas) has produced a COVID-19 vaccine that passed an early trial, with all patients producing antibodies, although some reported severe side effects to the vaccine in the trial. The vaccine will be tested in another, much larger trial later this month.

  • OILUSAUG20 (WTI) and OILUKSEP20 (Brent) - continue to see small trading ranges with Brent and WTI having settled close to $43/b and $40/b for the past two weeks. The market trades higher today with high OPEC+ compliance and vaccine focus overshadowing U.S. virus-related demand fears. Last night the API reported an 8.32-million-barrel drop in U.S. crude oil stocks and if confirmed it would be the biggest weekly drop since December. The market will be looking for confirmation from the EIA later today with surveys only looking for a small change. The OPEC+ group is expected to relax production cuts by 2 million barrels/day from August. Initially by less due to compensatory output cuts from laggard members over the next couple of months.

  • XAUUSD (Spot Gold) and XAGUSD (Spot Silver) - both trades close their recent highs as the dollar keep testing support and real yields trade softer after Fed Governor Brainard painted a dark picture of the U.S. economic outlook. Tensions between the U.S. and China also adding some support while the progress towards developing a coronavirus vaccine weighs. Supported by coppers continued bid silver has led from the front with the XAUXAG ratio falling to 93.7, the lowest since February. Focus on resistance at $1818 in gold while silver could be targeting the 2019 high at $19.65.

  • EURUSD – the EURUSD supermajor had a look above the key 1.1400 area yesterday and overnight, and even tested the 1.1422 high from June. Traders may be reluctant to take the pair higher with an ECB meeting up tomorrow, though this meeting may produce few surprises. One interesting development over the last couple of sessions is a seeming lack of positive correlation with the ups and downs in the equity market, a possible sign that the move has more conviction, though it will be important for the pair, now that it has come this far, to clear the 1.1400-1.1500 hurdle.

  • AUDUSD – the resurgence in risk appetite from yesterday’s weak spot has helped the Aussie higher across the board, and AUDUSD has cleared very tactical range resistance in a very quiet market recently and even poked above the key 0.7000 level, with nominal intraday highs extending as far as 0.7063 in early June, though the highest daily close was 0.7021. Whether this pair can clear the key range resistance higher, together with a similar technical set-up in EURUSD, is important to watch for the broader status of the US dollar and whether it is set to weaken.

What is going on?

  • US Federal Reserve’s Deputy Governor Brainard was out with a very dovish speech, saying it was time for the Fed to pivot monetary policy to providing more accommodation as she waxed very pessimistic on the current state of the US economy:” A thick fog of uncertainty still surrounds us, and downside risks predominate.” Brainard mentioned forward guidance and yield-curve control as policy options worth consideration.

  • The Trump administration signed the Hong Kong Autonomy Act, new legislation that will give his administration more leeway in imposing sanctions on Chinese officials and entities. President Trump also signed an order that rescinds Hong Kong’s special trade status – all of this bringing risk of retaliation from China (that it has in fact already promised and a generally escalation in the negative trend in US-China relations.

  • China made its biggest purchase ever of U.S. corn the USDA said yesterday. While political tensions between the U.S. and China remain elevated the selling of 1.7 million metric corns by U.S. exporters was taken as a sign the phase one trade deal remains alive. However, this the second big purchase of U.S. corn within a week has not managed to move the price because rains are currently improving the outlook for yields.

What we are watching next?

  • Q2 earnings season starts this week with financials in focus. See our Q2 earnings preview from Peter Garny. Today's top names include Goldman Sachs (GS:xnys, today 1130 GMT) and healthcare giant UnitedHealth Group (UNH:xnys) reporting before the market open. But the highlight of the week, given its parabolic rise to new all-time highs after the COVID-19 meltdown is Netflix (NFLX:xnas, Thursday). According to earnings estimates Q2 earnings will be the worst since 2011 but it will also be the most exciting in many years as 80% of S&P 500 companies skipped their guidance in Q1 leaving investors to fly blind into the storm. With US technology stock valuations at record levels there is little margin for error so any revenue miss could lead to steep declines. The record high index weight concentration in S&P 500 by the large technology stocks mean that their results will make or break the equity market over the summer months.

  • Risk of COVID-19 linked shutdowns spreading and the daily mortality numbers across the Sun Belt states this week and in coming weeks after a rise last week as a key metric for whether of deaths are set to surge in proportion to case count. This is a rough indicator on the risk of severe new lockdowns and whether widened testing is the chief driver of the new case count (presumably capturing many asymptomatic carriers) and/or whether treatment of the disease has vastly improved or even whether the disease itself has mutated and become less deadly.

Economic Calendar Highlights (times GMT)

  • 12:30 – US Jul. Empire Manufacturing Survey
  • 13:15 – US Jun. Industrial Production and Capacity Utilization
  • 14:00 – Canada Bank of Canada Rate Decision
  • 14:30 – EIA's Weekly Inventory Report
  • 16:00 – US Fed’s Harker (FOMC Voter) to Speak
  • 18:00 – US Fed Releases Beige Book
  • 22:45 – New Zealand Q2 CPI
  • 01:30 – Australia Jun. Unemployment Rate and Employment Change
  • 02:00 – China Q2 GDP
  • 02:00 – China Jun. Industrial Production and Retail Sales

Follow SaxoStrats on the daily Saxo Markets Call on your favorite podcast app:

Apple Sportify Soundcloud Stitcher

Disclaimer

Confidentiality and Usage:
You may not reproduce, distribute, or transmit this material or any portion thereof without prior written permission from Saxo.

Nature of Information:
The information provided herein is based on current market conditions and analysts' opinions, which may reflect personal views of the author, and are subject to change without notice. This material does not include a record of any trading prices, or an offer of, or solicitation for, or endorsement to enter into any transaction in any investment product. Any forecast on the economy, markets and economic trends of the markets provided is not necessarily indicative of the future or likely performance of the investment product subject of this material.

Responsibility and Liability:
Saxo accepts no liability for any use that may be made of these comments or for any consequences that arise from such use. Saxo does not guarantee the accuracy or completeness of any information provided and assumes no liability for any errors, omissions, losses, or damages resulting from the use of this information.

The information provided in this material is solely for information only. It is intended for general circulation and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. Accordingly, it should not be relied on or treated as a substitute for specific advice concerning specific situations of any person. Please seek advice from a financial adviser regarding the suitability of any investment product taking into account your specific investment objectives, financial situation or particular needs before you make a commitment to purchase an investment product. In the event that you choose not to seek advice from a financial adviser, you should consider whether any investment product mentioned in this publication is suitable for you.

Notwithstanding the above, insofar as any information provided herein contains research analyses or reports concerning any investment product authored by any foreign research house and is issued or promulgated to a person in Singapore who is not an accredited investor, expert investor, and/or institutional investor, Saxo Capital Market Pte. Ltd. accepts legal responsibility for the contents of this material to the extent required by law. Recipients of such material are to contact Saxo Capital Markets Pte. Ltd. in respect of any matters arising from, or in connection with, this material.

Risk Disclosure:
Trading in investment products involve significant risk, including the risk of losing your entire investment. Historical returns are not a guarantee of future returns. Prices can both rise and fall, and there is a risk that you will not get back the money you invested.

Conflicts of interest:
The author may hold positions in the investment products mentioned. The author does not own positions in the underlying investment product exceeding 0.5% of its market capitalisation, save as otherwise declared. The author is not permitted to trade the mentioned investment products within the first 24 hours after the publication of this article.

Saxo maintains partnerships with companies that compensate Saxo for promotional activities conducted on its platform. Additionally, Saxo has agreements with certain partners who provide retrocession contingent upon clients purchasing specific investment products offered by these partners. While Saxo receives compensation from these partnerships, all content is conducted with the intention of providing clients with valuable options and information.

Publication details:
If any listed companies are the subject of the material, the content has not been submitted to the companies in question prior to publication.

Please refer to our full disclaimer and notification on non-independent investment research for more details.

Saxo Markets
88 Market Street
CapitaSpring #31-01
Singapore 048948

Contact Saxo

Singapore
Singapore

Saxo Capital Markets Pte Ltd ('Saxo Markets') is a company authorised and regulated by the Monetary Authority of Singapore (MAS) [Co. Reg. No.: 200601141M ] and is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms & Risk Warning to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Saxo is part of the J. Safra Sarasin Group.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Trading in leveraged products such as Margin FX products may result in your losses exceeding your initial deposits. Saxo Markets does not provide financial advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Markets does not take into account an individual’s needs, objectives or financial situation.

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-sg/about-us/awards.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website are not intended for residents of the United States, Malaysia and Japan. Please click here to view our full disclaimer.

This advertisement has not been reviewed by the Monetary Authority of Singapore.

Apple and the Apple logo are trademarks of Apple Inc, registered in the US and other countries and regions. App Store is a service mark of Apple Inc. Google Play and the Google Play logo are trademarks of Google LLC.